I don't know what the percentage is. I just know from my experience that I made money. I was just disputing his Fact, as being merely an opinion, which it was. His Fact was not a Fact.
RS are actually a good short term play, you can get a nice POP, as I did. That stock I had is still up about 250% from where it RS, and that has been almost a year. It never went back to pre RS levels.
It really depends on the company and how they handle things.
If they continue diluting at a rapid pace, sure they will go back down.
I think it could be different here. With FDA approval, I would expect to stating showing sales growth, which should mean less dilution. You put some new management in, and you should see really big gains. The RS would be to get the price high enough, they could uplist, which would bring in some more serious investors.
BIEL could be different, its worth watching to me.